GlassScriptPhysician profile
Sarah Riehl
NPI 1104053206
$3,563.98
in general payments reported to CMS, 2019-2025
21 companies · $1,106 in 2025
The $1,106 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $407 · 2020: $241 · 2021: $15.35 · 2022: $101 · 2023: $667 · 2024: $1,026 · 2025: $1,106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,787 · Education: $12.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,786.62 |
| Education | $12.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $680.60 | 2021-2025 | |
| Lundbeck LLC | $575.13 | 2019-2025 | Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $464.67 | 2023-2025 | Caplyta |
| Corium, LLC | $377.68 | 2023-2025 | Azstarys |
| Takeda Pharmaceuticals U.S.A., INC. | $240.42 | 2019-2025 | Trintellix |
| Janssen Pharmaceuticals, INC | $192.99 | 2019-2024 | Spravato |
| Ironshore Pharmaceuticals INC. | $180.29 | 2019-2024 | Jornay Pm |
| Otsuka America Pharmaceutical, INC. | $135.88 | 2019-2025 | Rexulti |
| Supernus Pharmaceuticals, INC. | $118.78 | 2022-2025 | Qelbree, Qelbree |
| Tris Pharma INC | $90.88 | 2019-2025 | Onyda Xr, Dyanavel Xr |
| Axsome Therapeutics, INC. | $87.57 | 2024-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $78.75 | 2020 | |
| Avanir Pharmaceuticals, INC. | $75.69 | 2019 | |
| Alkermes, INC. | $73.20 | 2023-2025 | Lybalvi |
| Collegium Pharmaceutical, INC. | $66.86 | 2025 | Jornay Pm |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Owp Pharmaceuticals, INC. | $34.14 | 2023-2025 | Subvenite, Lamotrigine |
| Idorsia Pharmaceuticals US INC | $24.16 | 2025 | Quviviq |
| Adlon Therapeutics L.P. | $19.25 | 2020 | |
| Arbor Pharmaceuticals, INC. | $17.57 | 2019 | |
| Sage Therapeutics, LLC | $15.91 | 2025 | Zurzuvae |
| Allergan, INC. | $13.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Riehl listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.